Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Fosnetupitant chloride hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Helsinn Group launches Akynzeo injection in US market
    Helsinn Group launches Akynzeo injection in US market

    26 Jun 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=169969&sid=2

    PHARMABIZ
    26 Jun 2024
    Share Share
    Helsinn's AKYNZEO® Injection Now Available in Ready-to-Use Vial in the US
    Helsinn's AKYNZEO® Injection Now Available in Ready-to-Use Vial in the US

    24 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/24/2902897/0/en/Helsinn-Group-announces-AKYNZEO-fosnetupitant-palonosetron-injection-is-now-available-in-a-ready-to-use-vial-in-the-US.html

    GLOBENEWSWIRE
    24 Jun 2024
    Share Share
    Glenmark introduces medication to prevent chemotherapy-induced nausea
    Glenmark introduces medication to prevent chemotherapy-induced nausea

    23 Jan 2023

    // ECONOMIC TIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-introduces-medication-to-prevent-chemotherapy-induced-nausea/articleshow/97243641.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

    ECONOMIC TIMES
    23 Jan 2023
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Fosnetupitant Chloride Hydrochloride and Palonosetron Hydrochloride
    FDA Confirms Paragraph IV Patent Litigation for Fosnetupitant Chloride Hydrochloride and Palonosetron Hydrochloride

    13 Jun 2022

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-fosnetupitant-chloride-hydrochloride-and-palonosetron-hydrochloride-1655270132.pdf

    FDA
    13 Jun 2022
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Aprepitant, Azilsartan, Bupivacaine, Cladribine, Elrombopag, Fosnetupitant, Fostamatinib, Ivacaftor and Sodium Thiosulfate.
    FDA Confirms Paragraph IV Patent Litigation for Aprepitant, Azilsartan, Bupivacaine, Cladribine, Elrombopag, Fosnetupitant, Fostamatinib, Ivacaftor and Sodium Thiosulfate.

    13 Jun 2022

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-aprepitant-azilsartan-bupivacaine-cladribine-elrombopag-fosnetupitant-fostamatinib-ivacaftor-and-sodium-thiosulfate-1655270821.pdf

    FDA
    13 Jun 2022
    Share Share
    Taiho Pharmaceutical Submits New Drug Application for NK1 Receptor
    Taiho Pharmaceutical Submits New Drug Application for NK1 Receptor

    23 Mar 2021

    // PRESS RELEASE

    https://www.taiho.co.jp/en/release/2021/20210323.html

    PRESS RELEASE
    23 Mar 2021
    Share Share